Releases
PTPI
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Petros Pharmaceuticals Inc (PTPI) stock and general news. This information may help you make smarter investment decisions.
About PTPI
Petros Pharmaceuticals, Inc. is a pharmaceutical company that is focused on men’s health therapeutics with a range of commercial capabilities, including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing and distribution. Its Stendraas is the United States Food and Drug Administration (FDA) approved phosphodiesterase 5 (PDE-5) inhibitor prescription medication for the treatment of erectile dysfunction (ED) and is the only patent-protected PDE-5 inhibitor on the market. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products of the Company are committed to identifying and developing other pharmaceuticals to advance men’s health, which is H100, which is the topical formulation candidate for the treatment of acute Peyronie’s disease.